• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (50)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Psychiatry  • Obsessive-Compulsive Disorder  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article by Dodd et al¹ described 11 patients with Parkinson disease who developed pathological gambling. The authors concluded that because pramipexole was the agonist involved in 9 of the 11 cases, and in 10 of 17 cases reported in the literature, pramipexole may result in gambling to a higher degree as compared with the other agonists, due to its disproportionate stimulation of dopamine D₃ receptors.

However, although the majority of patients with pathological gambling were taking pramipexole in this study, the total number of patients who were treated with the various agonists was not reported. If many more patients were treated with pramipexole as compared with the other 2 agonists (which is the case in many centers in North America), then it may appear that pramipexole is more responsible than the other agonists unless the denominator (total number of treated patients) is included in the assessment. Similarly, the small . . . [Full Text of this Article]

AUTHOR INFORMATION

Cathy Lu, BSc; Aamir Bharmal; Oksana Suchowersky, MD, FRCPC, FCCMG

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
M. Leann Dodd, Kevin J. Klos, James H. Bower, Yonas E. Geda, Keith A. Josephs, and J. Eric Ahlskog
Arch Neurol. 2005;62(9):1377-1381.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease
Rodriguez-Oroz et al.
Brain 2011;134:36-49.
ABSTRACT | FULL TEXT  

Dopamine, Reward, and Frontostriatal Circuitry in Impulse Control Disorders in Parkinson's Disease: Insights from Functional Imaging
Ray and Strafella
Clin EEG Neurosci 2010;41:87-93.
ABSTRACT | FULL TEXT  

Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management
Wu et al.
Postgrad. Med. J. 2009;85:590-596.
ABSTRACT | FULL TEXT  

The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow et al.
Neurology 2009;72:S1-S136.
ABSTRACT | FULL TEXT  

Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study
Steeves et al.
Brain 2009;132:1376-1385.
ABSTRACT | FULL TEXT  

Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease
Voon and Fox
Arch Neurol 2007;64:1089-1096.
ABSTRACT | FULL TEXT  

Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease
Smeding et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:517-519.
ABSTRACT | FULL TEXT  

Recognition and management of neuropsychiatric complications in Parkinson's disease
Ferreri et al.
CMAJ 2006;175:1545-1552.
ABSTRACT | FULL TEXT